Step by Stepa HemeOncBuddy patient portal

Tremelimumab

Illustration: Tremelimumab

Say it: trem-eh-LIM-yoo-mab · Brand names: Imjudo

Tremelimumab is an immunotherapy medicine that helps your own immune system fight cancer.

What it is

Immune cells have a brake called CTLA-4 that keeps them calm. Tremelimumab blocks this brake. This helps more immune cells wake up and fight the cancer.

Often used for

How you get it

Tremelimumab is given through a vein (IV) in a clinic. The infusion takes about 1 hour. For liver cancer it is often given just once. For lung cancer it may be given a few times, every 3 to 6 weeks. Your schedule may be different.

Common side effects and what helps

Call your care team right away if you have

Before you start, tell your team

Good to know

Questions to ask

Side effect guides

Sources

Quick answers

What is Tremelimumab?
Tremelimumab is an immunotherapy medicine that helps your own immune system fight cancer. Brand names: Imjudo.
What is Tremelimumab used for?
liver cancer, given with durvalumab; non-small cell lung cancer, given with durvalumab and chemotherapy.
How is Tremelimumab given?
Tremelimumab is given through a vein (IV) in a clinic. The infusion takes about 1 hour. For liver cancer it is often given just once. For lung cancer it may be given a few times, every 3 to 6 weeks. Your schedule may be different.
What are the common side effects of Tremelimumab?
Diarrhea. Rash or itchy skin. Feeling tired. Upset stomach. Not feeling hungry. Fever.
When should I call my care team while taking Tremelimumab?
Diarrhea, belly pain, or bloody or black stools; A new or worse cough, chest pain, or shortness of breath; Yellow skin or eyes, very dark pee, or pain on the right side of the belly; Bad headache, extreme tiredness, dizziness, or feeling very cold or very hot; Feeling very thirsty, peeing a lot, or confusion (signs of high blood sugar); Chest pain, a fast or uneven heartbeat, or muscle weakness; A rash with blisters, peeling skin, or sores in the mouth.

Last updated: 2026-10-27. Medically reviewed by Veli Bakalov, MD, medical oncologist (October 2026). General education from Step by Step, the patient portal of HemeOncBuddy.